{"entity":{"id":"nct06422143","kind":"trial","name":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287","aka":[],"tldr":"A phase 3 trial of Pembrolizumab, Sacituzumab tirumotecan, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]. ClinicalTrials.gov record last updated 2026-10-06: recruiting. Enrollment is planned at 851 participants. Primary completion is estimated at 2029-01-12. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Pembrolizumab, sac-TMT, Carboplatin, Paclitaxel, Nab-paclitaxel. Registered primary measures: Overall survival (OS).","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06422143","url":"https://clinicaltrials.gov/study/NCT06422143"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":["adc","checkpoint-inhibitor","cytotoxic-chemotherapy","platinum","topoisomerase-inhibitors"],"targets":["trop2"],"drugs":["pembrolizumab","sacituzumab-tirumotecan","carboplatin","paclitaxel"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-10-06: recruiting. Enrollment is planned at 851 participants. Primary completion is estimated at 2029-01-12. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT06422143","phase":"3","setting":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]","sponsor":"Merck Sharp & Dohme LLC","participation":[{"nct":"NCT06422143","source":"https://clinicaltrials.gov/study/NCT06422143","fetchedAt":"2026-10-07T16:54:39.727Z","studySha256":"e424d426511952d26ffb2a793ce0526536e70379c8193d87a3058ca38efa7735","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-06","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":851,"enrolmentType":"ESTIMATED","siteCount":216,"recruitingSiteCount":172,"countries":["Argentina","Austria","Brazil","Canada","Chile","China","Colombia","Czechia","France","Germany","Hungary","Ireland","Israel","Italy","Japan","Peru","Poland","Romania","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Arab Emirates","United Kingdom","United States"]}],"started":"2024-06-10","startedType":"actual","enrolled":851,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06422143/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}